Our Technology

Our approach kills cancer cells and displays cancer specific antigens directly to the immune system, providing personalized therapy by in-situ immunization. There is no need for pre-treatment sequencing. CyPep-1 has strong single agent activity and synergizes with checkpoint inhibitors. Watch the animation below to learn more about how our technology works.